Avacta Group PLC AVCTF

Stock OTCM Rating as of Oct 2, 2026

$0.94 −0.02 (2.31%)

As of Sep 24, 2026, 6:10:43 PM Delayed Price Closed

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History

AVCTF is trading at a LOCK|f#Prl premium.

Price

$0.94

Oct 2, 2026

Fair Value

LOCK|>^QnK&

Sep 26, 2026

Uncertainty

LOCK|^h >t>P

1-Star Price: LOCK|#<!Rhh
5-Star Price: LOCK|Cn@r#n&
Economic Moat: LOCK|@S<@W
Capital Allocation: —

Trading Information

Previous Close Price: $0.96
Day Range: $0.94–0.94
52-Week Range: $0.75–1.23
Bid/Ask: $0.59 / $1.43
Shares Outstanding: 456.96M
Market Cap: $425.21M
Volume/Avg: 3,300 / 6,368

Key Statistics

Price/Earnings (Normalized): —
Price/Sales: 2,687.52
Dividend Yield (Trailing): 0.00%
Dividend Yield (Forward): 0.00%
Dividend Payment Schedule: —
Total Yield: —

Company Profile

Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.

Sector: Healthcare
Industry: Biotechnology
Stock Style Box: Small Growth
Total Number of Employees: 75
Website: https://avacta.com

Valuation

Metric	AVCTF
Price/Earnings (Normalized)	—
Price/Book Value	85.77
Price/Sales	2,687.52
Price/Cash Flow	—

Price/Earnings

No chart available

Financial Strength

Metric	AVCTF
Quick Ratio	0.95
Current Ratio	0.95
Interest Coverage	−4.86

Quick Ratio

AVCTF

Profitability

Metric	AVCTF
Return on Assets (Normalized)	−112.85%
Return on Equity (Normalized)	−1,601.77%
Return on Invested Capital (Normalized)	−150.39%

Return on Assets

AVCTF

Biotechnology Industry Comparables

Screen With Investor

Name	Capital Allocation	Economic Moat	Market Cap
Vertex Pharmaceuticals Inc VRTX	LOCK\|XT#gdj	LOCK\|$&?f#	$128B
Moderna Inc MRNA	LOCK\|?&>t!<	LOCK\|^Y	$76B
Regeneron Pharmaceuticals Inc REGN	LOCK\|pSnXL@$	LOCK\|><<l#	$76B
argenx SE ADR ARGX	LOCK\|^#&<&Q	LOCK\|&qq	$57B
BeOne Medicines Ltd ADR ONC	LOCK\|<$DG>N!	LOCK\|$<	$41B
Alnylam Pharmaceuticals Inc ALNY	LOCK\|$<^K#F	LOCK\|>%N>$	$29B
Royalty Pharma PLC Class A RPRX	LOCK\|sv$^mywj	LOCK\|@<>YF	$25B
BioNTech SE ADR BNTX	LOCK\|#F^^w@	LOCK\|Fcm	$24B
Incyte Corp INCY	LOCK\|Y>j!br%	LOCK\|D^@	$23B
Jazz Pharmaceuticals PLC JAZZ	LOCK\|sM%V#k	LOCK\|yGk	$15B